SELECT PUBLICATIONS

Arkenau H et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc ASCO 2005;Abstract 3507.

Cassidy J et al. Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase II trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for Dukes’ C colon cancer: No differences in treatment arms that could inf luence survival outcome. Proc ASCO 2005;Abstract 3586.

Fernando N et al. A phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of metastatic colorectal cancer. Proc ASCO 2005;Abstract 3556.

Glynne-Jones R et al. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: How successful have we been? Ann Oncol 2006;17(3):361-71. Abstract

Glynne-Jones R et al. Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). Proc ASCO 2005;Abstract 3527.

Grothey A. Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy? Nat Clin Pract Oncol 2006;3(1):22-3. No abstract available

Hochster HS et al. Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. Proc ASCO GI Cancers Symposium 2006;Abstract 244.

Hochster HS et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. Proc ASCO GI Cancers Symposium 2005a;Abstract 241.

Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies. Proc ASCO 2005b;Abstract 3515.

Jain RK et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40. Abstract

Sastre J et al. Preliminary results of a randomized phase III trial of the TTD group comparing capecitabine and oxaliplatin (CapeOx) vs oxaliplatin and 5-fluorouracil in continuous infusion (5-FU CI) as first-line treatment in advanced or metastatic colorectal cancer (CRC). Proc ASCO 2005;Abstract 3524.

Schmoll HJ et al. Safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) versus bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc ASCO GI Cancers Symposium 2006;Abstract 278.

Tabernero J et al. Capecitabine and oxaliplatin (Xelox) in combination as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): Results of an international multicenter phase II trial. Proc ASCO 2002;Abstract 531.

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704. Abstract

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005;Abstract 3521.

Twelves CJ et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: Post hoc analysis of a large phase II study. Clin Colorectal Cancer 2005;5(2):101-7. Abstract